Healthcare Sector Announced Reforms, Financial Results, Public Offerings, Top Rankings and Positive Data - Research Report on Kindred, Zogenix, Sangamo, PhotoMedex and Supernus Pharmaceuticals

Editor Note: For more information about this release, please scroll to bottom.

News provided by

Nov 19, 2013, 08:00 ET

NEW YORK, November 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Kindred Healthcare Inc. (NYSE: KND), Zogenix, Inc. (NASDAQ: ZGNX), Sangamo BioSciences Inc. (NASDAQ: SGMO), PhotoMedex, Inc. (NASDAQ: PHMD) and Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Kindred Healthcare Inc. Research Report

On November 8, 2013, Kindred Healthcare Inc. (Kindred) issued a press release regarding its blueprint for healthcare reform. The Company stated that in order to play a positive role in advancing the discussion surrounding post-acute reform, it appreciated the recent opportunity to submit their Roadmap for Post-Acute Reform to the leadership of the Senate Finance and House Ways & Means Committees. Kindred stated that it could provide constructive input and feedback as they have learned valuable lessons in their efforts to transform their own service delivery model to provide integrated, patient-centered care across the post-acute continuum to support new payment models based on value, not volume. The Full Research Report on Kindred Healthcare Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ab58_KND

Zogenix, Inc. Research Report

On November 12, 2013, Zogenix, Inc. (Zogenix) reported the closing of its previously announced public offering of 30.7 million shares of its common stock, including 4 million shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters, at a price to the public of $2.25 per share. According to the Company, the aggregate net proceeds to Zogenix from this offering are expected to be approximately $64.4 million, after deducting underwriting discounts and commissions and estimated offering costs. Zogenix stated that it intends to use the net proceeds from the offering to fund pre-commercialization and commercialization activities for ZohydroTM ER, additional development activities of Zohydro ER and Relday^[^TM^], and for working capital and other general corporate purposes. Zogenix also mentioned that it may use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products. The Full Research Report on Zogenix, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ef36_ZGNX

Sangamo BioSciences Inc. Research Report

On November 12, 2013, Sangamo BioSciences Inc. (Sangamo BioSciences) announced that positive preclinical data from their joint program with Shire plc to develop a novel ZFP Therapeutic approach to Huntington's disease (HD) were presented at the 2013 Annual Meeting of the Society for Neuroscience. The Company's Vice President of Research and Chief Scientific Officer Philip Gregory, D. Phil. said, "Huntington's disease is a monogenic disease with a distinct DNA signature and we believe that ZFP technology, which is highly specific and functions at the DNA level, provides the best therapeutic approach to address this intractable disease. We are very pleased with the progress of this program and particularly these encouraging preclinical data. With Shire we are committed to developing treatment options for conditions that have significant unmet patient need, such as HD." The Full Research Report on Sangamo BioSciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/52a6_SGMO

PhotoMedex, Inc. Research Report

On November 13, 2013, PhotoMedex, Inc. (PhotoMedex) announced that it was ranked No. 143 on Deloitte's Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. PhotoMedex stated that it grew 925% during this period. According to the Company, Dr. Dolev Rafaeli, PhotoMedex CEO, credits the strong success of the Company's XTRAC excimer laser for psoriasis and vitiligo and no!no! brand hair removal device with its 925% revenue growth. Dr. Dolev Rafaeli said, "Our XTRAC business has nearly doubled in the past year, with more than 500 practices in the U.S. offering XTRAC therapy. We've also seen significant increases with the launch of the no!no! Hair PRO in the U.S. and through sales of no!no! products worldwide." The Full Research Report on PhotoMedex, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/bcc6_PHMD

Supernus Pharmaceuticals, Inc. Research Report

On November 12, 2013, Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals) reported its financial results for Q3 2013. The Company reported net loss of $24.1 million or $0.78 per basic and diluted share, compared to net loss of $13.5 million or $0.13.5 per basic and diluted share in Q3 2012. Commenting on the results, President and CEO, Jack Khattar said, "As we expected in the third quarter we received approval by the FDA for Trokendi XR and were able to launch it one week later. Our business is now experiencing accelerated growth with product shipments to wholesalers reaching $13.8 million by the end of the third quarter and $17.9 million by the end of last week. Oxtellar XR prescriptions have doubled in the third quarter as compared to the second quarter and Trokendi XR is off to a great start. Our Company continues to execute very well on our two product launches." The Full Research Report on Supernus Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1ccb_SUPN

----

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
For any urgent concerns or inquiries, please contact us at [email protected].
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner